TOP TIPS: Anti-graft compliance for drug industry

As allegations of GlaxoSmithKline corruption spreads across the globe, China consultants at Protiviti advise on how to effectively screen drug suppliers and perform better internal control.

By I-Ching Ng

May 14, 2014

linkedin facebook twitter

China’s Ministry of Public Security is set to update journalists on the alleged corrupt activities of GlaxoSmithKline (GSK) today. The saga of GSK and ongoing investigations is again in the spotlight.

Sign-in to access CorporateTreasurer content.

Please sign in to your subscription to unlock full access to our premium CT resources.

Free Registration & 7-Day Trial

Note: This free trial is a one-time offer. You are eligible for one free trial per year.

If you are a treasurer, CFO or senior finance professional at a corporate, please register to the website here.

Questions?

If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Risk & Compliance Treasury